<DOC>
	<DOC>NCT02611713</DOC>
	<brief_summary>This study is a non-interventional post-marketing observational study (PMOS) of participants with advanced Parkinson's disease (PD) treated with Duodopa/Duopa in a routine clinical setting. Effectiveness of treatment will be collected with physician and participant/caregiver health outcomes beginning with PMOS enrollment (baseline visit), at the start of Duodopa/Duopa treatment via percutaneous endoscopic gastrostomy-with jejunal extension (PEG-J), at regularly scheduled visits closest to Months 3 and 6, and every 6 months thereafter up to 36 months.</brief_summary>
	<brief_title>Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa, levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Eligibility for Duodopa/Duopa therapy in accordance with the approved local Duodopa/Duopa label in the participating country. Duodopa/Duopa na√Øve participants Decision to treat with Duodopa/Duopa made by the physician prior to any decision to approach the participant to participate in this study Prior to any studyrelated procedures being performed, the participant, or legal authorized representative (LAR) has voluntarily signed an Authorization for Use/Disclosure of Data (AUDD)/informed consent form (ICF) according to national regulations after the study has been explained and the subject has had the opportunity to have questions answered. Any condition included in the contraindications section of the approved local Duodopa/Duopa label in the participating country. Participants who have had previous surgery for PD including, but not limited to deep brain stimulation (DBS) or cell transplantation. Participants currently in treatment with continuous apomorphine infusion. In case of a previous treatment with continuous subcutaneous apomorphine infusion, there must be at least 4 weeks between discontinuation of this treatment and inclusion into this study. MiniMental State Examination (MMSE) score &lt;24 Participation in a concurrent interventional clinical trial. Lack of motivation or insufficient language skills to complete the study questionnaires</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>effectiveness</keyword>
	<keyword>Caregiver Burden</keyword>
	<keyword>motor and non-motor symptoms</keyword>
	<keyword>Duodopa/Duopa</keyword>
	<keyword>fluctuations</keyword>
	<keyword>OFF time</keyword>
	<keyword>carbidopa levodopa enteral suspension (CLES)</keyword>
	<keyword>dyskinesia</keyword>
	<keyword>Observational</keyword>
	<keyword>tremor</keyword>
	<keyword>levodopa-carbidopa intestinal gel (LCIG)</keyword>
	<keyword>Quality of Life</keyword>
	<keyword>Advanced Parkinson's Disease</keyword>
	<keyword>Long-term</keyword>
</DOC>